Zivo Bioscience, Inc.

Businessfiled

Zivo Bioscience, Inc. operates in Biotech, based in Bloomfield Hills.

Sub-sector tags: biotech.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Zivo Bioscience, Inc. has raised $15M in disclosed capital across 16 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $5.0M on 2018-07-01.

Most recent recorded round closed around 2023-06-30.

Filings read as a recurring offering program rather than a clean venture-stage ladder — interpret stage labels and step-ups with that in mind.

Valuation (modeled)modeled

Provath models Zivo Bioscience, Inc. at approximately $34M (range $4.4M–$93M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.67× the median modeled value of Series A Biotech companies in 2022–2024 (12 peers) — value vs value, same stage and era. Within the normal band (67% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 4 months.

Last raise 3.0 yr ago; this sector typically re-raises about every 11 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round was 1.3× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 88% of Biotech peers (233 compared).

Modeled value ranks above 79% of those peers.

Closest niche peers: Epsilon3, Inc., Salish Bioscience Inc., HB Biotech, Inc., Acoustic Wave Cell Therapy, Inc., Mindstate Design Labs, Inc..

Peoplefiled

24 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.

Recurring-offering pattern: stage-based valuation has lower applicability.